Verapamil: An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension

D McTavish, EM Sorkin - Drugs, 1989 - Springer
Although verapamil is a well-established treatment for angina, cardiac arrhythmias and
cardiomyopathies, this review reflects current interest in calcium antagonists as …

[PDF][PDF] In the line of treatment: a systematic review of paroxysmal supraventricular tachycardia

F Ahmad, MA Sneineh, RS Patel, SR Reddy… - Cureus, 2021 - cureus.com
Paroxysmal supraventricular tachycardia (PSVT) is a common tachyarrhythmia, and an
electrocardiogram is the best tool for making a diagnosis. If Valsalva maneuvers and carotid …

Calcium antagonists: clinical use in the treatment of arrhythmias

BN Singh, K Nademanee, SH Baky - Drugs, 1983 - Springer
Calcium antagonists have recently emerged as a class of drugs for the treatment of angina,
hypertension and certain cardiac arrhythmias. Verapamil is the prototype calcium antagonist …

Clinical pharmacology of slow channel blocking agents

RG McAllister Jr - Progress in cardiovascular diseases, 1982 - Elsevier
Rational and effective pharmacotherapy requires an understanding of the patient's disease
process as well as an appreciation of both the pharmacodynamics and the …

Verapamil hydrochloride: pharmacological properties and role in cardiovascular therapeutics

MSH Baky, BN Singh - Pharmacotherapy: The Journal of …, 1982 - Wiley Online Library
Verapamil hydrochloride, a prototype calcium antagonist, is now marketed in the United
States for the acute treatment of supraventricular tachyarrhythmias and for chronic …

Verapamil in cardiac arrhythmias: an overview.

J Vohra - Clinical and Experimental Pharmacology & physiology …, 1982 - europepmc.org
1. Verapamil remains the most widely used calcium antagonist for the treatment of cardiac
arrhythmias. It is the most potent and effective drug for the acute treatment of paroxysmal …

Clinical applications of slow channel blocking compounds

AG Ellrodt, BN Singh - Pharmacology & therapeutics, 1983 - Elsevier
The slow-channel blockers constitute a structurally diverse group of drugs with varying
mechanisms of action, propensities for site of greatest cardiovascular activity, and clinical …

Calcium antagonists: a new class of therapeutic agents

A Gunawan, A Massumi, RJ Hall - Cardiovascular Diseases, 1981 - ncbi.nlm.nih.gov
A new class of therapeutic agents, sharing inhibition of the slow calcium channel, will soon
be available to the American patient. Selective action of these agents upon the …

Особенности антигипертензивной терапии при коморбидной патологии

СВ Недогода - Сердце: журнал для практикующих врачей, 2008 - elibrary.ru
Проблема выбора оптимального антигипертензивного препарата при сопутствующей
кардиальной и экстракардиальной патологии остается весьма актуальной, несмотря …

Management of Atrial Fibrillation: Identifying and treating the causes

SW Rabkin - Canadian Family Physician, 1991 - ncbi.nlm.nih.gov
Atrial fibrillation is relatively common, particularly among the elderly. Management requires
identifying and treating the causes. Treatment aims at improving overall cardiac status. A …